The fact that NONMEM7 will not be open source code is very unfortunate,
 
it has not been often,  but there have been occasions when by going over the 
source code I was able to understand aspects of NONMEM programming that were 
still unclear to me,
 
being able to get a look at the actual algorithms in software had been a major 
advantage for NONMEM!!!!
 
  
 
 
 
Alice I Nichols, PhD
Sr Director
Early Development and Clinical Pharmacology
Wyeth Research
500 Arcola Rd
Collegeville,  PA  19426
tel: 484-865-8741/ fax: 484-865-9075
[email protected] 

>>> "Serge Guzy" <[email protected]> 7/3/2009 3:56 AM >>>


I do have only one simple question. How many people took advantage from the 
fact Nonmem was distributed as open source? If we are talking about a very 
small percentage, is this discussion worthwhile? How many people except bob 
bauer and may be somebody else I am not aware of are able to follow and 
understand the cuirrent nonmem code?
Serge
From: [email protected] 
To: Ludden, Thomas ; [email protected] 
Sent: Thu Jul 02 23:46:09 2009
Subject: [NMusers] RE: NONMEM 7 Update 

 Thomas Didn't ICON consider that indeed, this decision might stimulate the 
divergence of an open-source clade of NONMEM, somewhat like R stemmed out of 
S-plus? If a small academic group starts to work in that direction, it would 
certainly be quickly joined by many* Thierry BuclinUniv. Hospital, Lausanne De 
: [email protected] [mailto:[email protected]] De la part 
de Ludden, Thomas
Envoyé : jeudi, 2. juillet 2009 15:15
À : Eleveld, DJ; [email protected] 
Cc : Krohn, Anthony
Objet : RE: [NMusers] NONMEM 7 Update

 Dear All:Icon Development Solutions has invested in the further development of 
NONMEM.  By mutual agreement with the University of California at San 
Francisco, NONMEM 7 is intellectual property belonging to IDS.  However, IDS 
will continue to pay royalties to UCSF.   The business plan under which NONMEM 
7 was developed calls for the protection of the I.P. involved.  In addition, 
NONMEM 7 contains several updated routines developed and owned by IMSL (Visual 
Numerics Inc.).  Our agreement with IMSL stipulates that we will not distribute 
their source code. The installer will compile the software but will not allow 
the unencrypted source code to remain on the users computer.  The licensing 
agreement will also stipulate that any attempt to access the source code will 
be a violation of the agreement. Some source code will be left unencrypted for 
various reasons, one being the need for users to change certain values in SIZES 
and perhaps other resource routines.Tom 
Thomas M. Ludden Ph.D.
Vice-President, Pharmacometrics R&D
ICON Development Solutions Tel: + 1 410 696 3040
Mob: + 1  410 258 2411
Fax:  + 1 410 480 0776
Email: [email protected]: www.icondevsolutions.com 


The information contained in this email message may contain confidential or 
legally privileged information and is intended solely for the use of the named 
recipient(s). No confidentiality or privilege is waived or lost by any 
transmission error. If the reader of this message is not the intended 
recipient, please immediately delete the e-mail and all copies of it from your 
system, destroy any hard copies of it and notify the sender either by telephone 
or return e-mail. Any direct or indirect use, disclosure, distribution, 
printing, or copying of any part of this message is prohibited. Any views 
expressed in this message are those of the individual sender, except where the 
message states otherwise and the sender is authorized to state them to be the 
views of XOMA. 

Attachment: Alice Nichols.vcf
Description: Binary data

Reply via email to